Company / Depreciation & Amortization
Amneal Pharmaceuticals, Inc. Depreciation & Amortization History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$60.7M
FY2023
5-year range
$60.7M / $63.3M
FY2019-FY2023
Trend
-
vs FY2022
Sector context
#29 of 168
Health Care
What the data says
Amneal Pharmaceuticals, Inc.'s depreciation & amortization of $61M is higher than 83% of companies in the Health Care sector (FY2023). Improved from $64M to $61M over the past 3 years.
Based on SEC 10-K filings.
$61M in FY2023 with a 5-year CAGR of +15.7%. Top quartile in the Health Care sector.
Improved from $64M to $61M over the past 3 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -2.0%
- 5-Year CAGR
- +15.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 17% in Health CareTop 83% of 168This company $60.7M Sector average $212.9M
▼
-71.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +15.7%, indicating consistent growth.
- Ranks #29 out of 168 companies in the Health Care sector.
- Peak depreciation & amortization was recorded in FY2020.
- Lowest depreciation & amortization in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 1.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $60.7M | - |
| FY2022 | - | - |
| FY2021 | $63.3M | -1.8% |
| FY2020 | $64.4M | +53.5% |
| FY2019 | $42.0M | +43.1% |
| FY2018 | $29.3M | - |
| FY2017 | - | - |
| FY2016 | $29.3M | - |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026